Xcellerex, Inc. received two Phase I contracts awarded by the Defense Advanced Research Projects Agency (DARPA) for the Accelerated Manufacture of Pharmaceuticals (AMP) program. The total funding for the two Phase I contracts is more than $13 million. The AMP program is focused on technologies for producing emergency therapeutics and vaccines, rapidly and cost effectively in order to respond to a range of biological threats. Phase I of the AMP program is focused on optimizing host strains that w...